MA31336B1 - Inhibiteurs de pi3k alpha a base de pyridopyrimidinone - Google Patents

Inhibiteurs de pi3k alpha a base de pyridopyrimidinone

Info

Publication number
MA31336B1
MA31336B1 MA32314A MA32314A MA31336B1 MA 31336 B1 MA31336 B1 MA 31336B1 MA 32314 A MA32314 A MA 32314A MA 32314 A MA32314 A MA 32314A MA 31336 B1 MA31336 B1 MA 31336B1
Authority
MA
Morocco
Prior art keywords
pyridoperimidineone
pi3k
depend
alpha inhibitors
compounds
Prior art date
Application number
MA32314A
Other languages
Arabic (ar)
English (en)
Inventor
Chris A Buhr
Longcheng Wang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA31336B1 publication Critical patent/MA31336B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des composés de formule (i). Les composés de l'invention inhibent, régulent, et/ou modulent l'activité de la kinase p13k et sont utiles dans le traitement de maladies hyperprolifératives, comme le cancer.
MA32314A 2007-04-11 2009-10-30 Inhibiteurs de pi3k alpha a base de pyridopyrimidinone MA31336B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11
PCT/US2008/004807 WO2008127712A1 (fr) 2007-04-11 2008-04-11 Composés pyrido [2, 3-d] pyrimidin-7-one utilisés en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA31336B1 true MA31336B1 (fr) 2010-04-01

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32314A MA31336B1 (fr) 2007-04-11 2009-10-30 Inhibiteurs de pi3k alpha a base de pyridopyrimidinone

Country Status (26)

Country Link
US (2) US20100209340A1 (fr)
EP (1) EP2142544B8 (fr)
JP (1) JP2010523681A (fr)
KR (1) KR20090130104A (fr)
CN (1) CN101711249A (fr)
AU (1) AU2008239596B2 (fr)
BR (1) BRPI0810175A2 (fr)
CA (1) CA2683820A1 (fr)
CO (1) CO6241119A2 (fr)
CR (1) CR11098A (fr)
DO (1) DOP2009000242A (fr)
EA (1) EA018964B1 (fr)
EC (1) ECSP099722A (fr)
ES (1) ES2425068T3 (fr)
HK (1) HK1139941A1 (fr)
IL (1) IL201209A0 (fr)
MA (1) MA31336B1 (fr)
MX (1) MX2009010815A (fr)
MY (1) MY150747A (fr)
NI (1) NI200900183A (fr)
NZ (1) NZ579945A (fr)
SV (1) SV2009003389A (fr)
TN (1) TN2009000389A1 (fr)
UA (1) UA101315C2 (fr)
WO (1) WO2008127712A1 (fr)
ZA (1) ZA200906648B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2590294A1 (fr) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyridopyrimidinones, dihydropyrimidopyrimidinones et pteridinones utiles en tant qu'inhibiteurs des kinases raf
KR20140033237A (ko) * 2005-10-07 2014-03-17 엑셀리시스, 인코포레이티드 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
EP1940839B1 (fr) * 2005-10-07 2013-07-31 Exelixis, Inc. INHIBITEURS DE PI3Kalpha DE TYPE PYRIDOPYRIMIDINONE
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
JP4718637B2 (ja) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用
EA020022B1 (ru) 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
EP2142543B8 (fr) * 2007-04-11 2013-07-03 Exelixis, Inc. Composés pyrido [2, 3-d]pyrimidin-7-one utilisés en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer
US8101622B2 (en) * 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
AU2010341573B2 (en) * 2009-12-22 2016-10-13 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2013056067A1 (fr) * 2011-10-13 2013-04-18 Exelixis, Inc. Composés pour une utilisation dans le traitement de carcinome des cellules basales
CN107375289A (zh) 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
EP1749004B1 (fr) * 2004-05-04 2007-09-19 Warner-Lambert Company LLC Pyrid[2,3-d]pyrimidin-7-ones pyrrolyl-substituees et derives de ces dernieres utilises comme agents therapeutiques
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
EP1940839B1 (fr) * 2005-10-07 2013-07-31 Exelixis, Inc. INHIBITEURS DE PI3Kalpha DE TYPE PYRIDOPYRIMIDINONE
AU2007284562B2 (en) * 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
JP4718637B2 (ja) * 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用

Also Published As

Publication number Publication date
KR20090130104A (ko) 2009-12-17
WO2008127712A1 (fr) 2008-10-23
US20130343988A1 (en) 2013-12-26
IL201209A0 (en) 2010-05-31
NI200900183A (es) 2010-10-05
AU2008239596B2 (en) 2013-08-15
EA200970936A1 (ru) 2010-02-26
EP2142544B8 (fr) 2013-07-03
AU2008239596A1 (en) 2008-10-23
BRPI0810175A2 (pt) 2014-12-30
NZ579945A (en) 2012-05-25
US20100209340A1 (en) 2010-08-19
DOP2009000242A (es) 2010-04-30
EA018964B1 (ru) 2013-12-30
JP2010523681A (ja) 2010-07-15
EP2142544B1 (fr) 2013-05-22
CO6241119A2 (es) 2011-01-20
CA2683820A1 (fr) 2008-10-23
CR11098A (es) 2010-01-27
TN2009000389A1 (en) 2010-12-31
SV2009003389A (es) 2010-04-27
UA101315C2 (ru) 2013-03-25
MX2009010815A (es) 2009-10-29
HK1139941A1 (en) 2010-09-30
EP2142544A1 (fr) 2010-01-13
MY150747A (en) 2014-02-28
ZA200906648B (en) 2010-04-28
ES2425068T3 (es) 2013-10-11
ECSP099722A (es) 2009-12-28
CN101711249A (zh) 2010-05-19

Similar Documents

Publication Publication Date Title
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
MA27933A1 (fr) Inhibiteurs de l'activite de akt
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
TW200714604A (en) Substituted heterocycles and the uses thereof
EA200800664A1 (ru) Производные пирролопиримидина в качестве ингибиторов syk
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA200870218A1 (ru) Замещенные имидазольные производные, композиции и способы применения в качестве ингибиторов ртразы
EA200800014A1 (ru) Аминохинолиновые и аминохиназолиновые модуляторы киназы
WO2007109045A8 (fr) composes organiques
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
EA200870048A1 (ru) ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
MA33155B1 (fr) Composes organiques et leurs utilisations
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
MX2012012031A (es) Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors